- The history of RLS
- RLS symptoms
- The impact of RLS on quality of life and sleep quality (including
- RLS diagnosis and management
Notes to Editor
About Restless Legs Syndrome (RLS)
Restless Legs Syndrome is a neurological disorder characterised by an uncontrollable urge to move the legs, usually accompanied by unpleasant and sometimes painful sensations in the legs. Restless Legs Syndrome affects up to ten percent of the population worldwide aged between 30 and 79 years(2) and around one-third of sufferers experience symptoms more than twice weekly causing moderate to severe distress.(5) The motor-restlessness worsens during the evening and night causing difficulty initiating and maintaining sleep. The sleep disruption can lead to excessive daytime sleepiness and compromise work performance. Restless Legs Syndrome also has considerable impact on social activities that require immobility.
About World Sleep Day
The World Sleep Day, an annual event which was put on the health agenda by the World Association of Sleep Medicine (WASM) in 2008, is intended to be a call to action on many fronts related to sleep including education, social issues and driving. The World Sleep Day Committee declare that "disorders of sleep are preventable and treatable medical conditions in every country of the world". The event is sponsored by the World Association of Sleep Medicine (WASM) and many local groups in different countries throughout the world.
World Sleep Day 2009 takes place on Friday, 20 March 2009. For more information please visit http://www.worldsleepday.org.
About the World Association of Sleep Medicine (WASM)
The World Association of Sleep Medicine (WASM) is an international organisation comprised of healthcare professionals primarily active in the field of sleep medicine. Its goal is to advance knowledge about sleep and sleep disorders among healthcare personnel and among the public worldwide and the Association was founded to improve sleep health worldwide and to encourage prevention and treatment of sleep disorders.
WASM is working towards increasing worldwide awareness of the importance of sleep and the adverse consequences resulting from lack of sleep, due either to enforced lifestyle or to sleep disorders themselves. The Association aims to act as a link between various sleep associations and cultures, i.e. as an international nexus among sleep clinicians and researchers in the advancement of worldwide sleep health. A special goal of the Association is to foster dissemination of expertise in sleep medicine everywhere in the world. For more information please visit http://www.wasmonline.org.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For more information please visit http://www.boehringer-ingelheim.com.
1. Allen RP et al. Restless Legs Syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001; 18(2): 128-147.
2. Phillips B et al. Epidemiology of Restless Legs Symptoms in adults. Arch Intern Med 2000; 160(14): 2137-2141.
3. Hening W et al. Impact, diagnosis and treatment of Restless Legs Syndrome in a primary care population: REST (RLS epidemiology, symptoms and treatment) primary care study. Sleep Med 2004; 5(3): 237-246.
4. Allen RP et al. Restless Legs Syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165(11): 1286-1292.
5. Silber MH et al. An algorithm for the management of Restless Legs Syndrome. Mayo Clin Proc 2004; 79(7): 916-922.
6. Allen RP et al. Restless Legs Syndrome: diagnostic criteria, special considerations, and epidemiology - A report from the Restless Legs Syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4(2): 101-119.
Contact: Ursula Bardon, Corporate Division Communications, Boehringer Ingelheim GmbH, 55216 Ingelheim/Germany, Phone: +49-6132-77-2622, Fax: +49-6132-72-2622, E-mail: email@example.com